Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration

被引：3

作者：

Takhar, Pam ^{[1
]}

Geirnaert, Marc ^{[2
]}

Gavura, Scott ^{[1
]}

Beca, Jaclyn ^{[1
,3
]}

Mercer, Rebecca E. ^{[1
,3
,4
]}

Denburg, Avram ^{[5
]}

Munoz, Caroline ^{[1
,3
]}

Tadrous, Mina ^{[6
,7
]}

Parmar, Ambica ^{[8
,9
]}

Dionne, Francois ^{[10
]}

Boehm, Darryl ^{[11
]}

Chambers, Carole ^{[12
]}

Craig, Erica ^{[13
]}

Trudeau, Maureen ^{[8
]}

Cheung, Matthew C. ^{[4
,8
,9
]}

Houlihan, Joanne ^{[14
]}

Mcdonald, Valerie ^{[15
]}

Pechlivanoglou, Petros ^{[15
]}

Taylor, Marianne ^{[16
]}

Wasylenko, Eric ^{[17
,18
]}

Wranik, Wieslawa Dominika ^{[19
,20
]}

Chan, Kelvin K. W. ^{[1
,3
,4
,8
,9
]}

机构：

[1] Ontario Hlth Canc Care Ontario, Toronto, ON M5G 2L3, Canada

[2] CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada

[3] Canadian Ctr Appl Res Canc Control, Toronto, ON M5G 2L3, Canada

[4] Sunnybrook Res Inst, Evaluat Clin Serv, Toronto, ON M4N 3M3, Canada

[5] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada

[6] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada

[7] Womens Coll Hosp, Toronto, ON M5S 1B2, Canada

[8] Sunnybrook Hlth Sci Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON M4N 3M3, Canada

[9] Univ Toronto, Temerty Fac Med, Toronto, ON M5S 1A8, Canada

[10] Prioritize Consulting Ltd, Vancouver, BC V6S 2B3, Canada

[11] Saskatchewan Canc Agcy, Regina, SK S4T 7T1, Canada

[12] Alberta Hlth Serv, Edmonton, AB T5J 3E4, Canada

[13] New Brunswick Canc Network, Fredericton, NB E3B 5G8, Canada

[14] Nova Scotia Hlth, Halifax, NS, Canada

[15] Hosp Sick Children, Child Hlth Evaluat Sci, Toronto, ON M5G 1X8, Canada

[16] BC Canc Agcy, Kelowna, BC V1Y 5L3, Canada

[17] Univ Calgary, Dept Oncol, Calgary, AB T2N 1N4, Canada

[18] Univ Alberta, John Dossetor Hlth Eth Ctr, Edmonton, AB, Canada

[19] Dalhousie Univ, Fac Management, Marine Affairs Program, Halifax, NS B3H 4R2, Canada

[20] Dalhousie Univ, Fac Med, Dept Community Hlth & Epidemiol, Halifax, NS B3H 4R2, Canada

来源：

CURRENT ONCOLOGY | 2024年 / 31卷 / 04期

基金：

加拿大健康研究院;

关键词：

oncology; decision-analysis; health technology assessment; multi-criteria decision analysis; CARE;

D O I：

10.3390/curroncol31040141

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multi-criteria decision analysis (MCDA) is a value assessment tool designed to help support complex decision-making by incorporating multiple factors and perspectives in a transparent, structured approach. We developed an MCDA rating tool, consisting of seven criteria evaluating the importance and feasibility of conducting potential real-world evidence (RWE) studies aimed at addressing uncertainties stemming from initial cancer drug funding recommendations. In collaboration with the Canadian Agency for Drugs and Technologies in Health's Provincial Advisory Group, a validation exercise was conducted to further evaluate the application of the rating tool using RWE proposals varying in complexity. Through this exercise, we aimed to gain insight into consensus building and deliberation processes and to identify efficiencies in the application of the rating tool. An experienced facilitator led a multidisciplinary committee, consisting of 11 Canadian experts, through consensus building, deliberation, and prioritization. A total of nine RWE proposals were evaluated and prioritized as low (n = 4), medium (n = 3), or high (n = 2) priority. Through an iterative process, efficiencies and recommendations to improve the rating tool and associated procedures were identified. The refined MCDA rating tool can help decision-makers prioritize important and feasible RWE studies for research and can enable the use of RWE for the life-cycle evaluation of cancer drugs.

引用

页码：1876 / 1898

页数：23

共 25 条

[1] A Step Toward the Development of the First National Multi-CriteriaDecision Analysis Framework to Support Healthcare Decision Making inSaudi Arabia [J].

Al-Jedai, Ahmed ;

Almudaiheem, Hajer ;

Alruthia, Yazeed ;

Althemery, Abdullah ;

Alabdulkarim, Hana ;

Ojeil, Rita ;

Alrumaih, Ali ;

Alghannam, Suliman ;

Almutairi, Abdulaali ;

Hasnan, Zuhair .

VALUE IN HEALTH REGIONAL ISSUES, 2024, 41 :100-107

[2] Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework [J].

Angelis, A. ;

Linch, M. ;

Montibeller, G. ;

Molina-Lopez, T. ;

Zawada, A. ;

Orzel, K. ;

Arickx, F. ;

Espin, J. ;

Kanavos, P. .

SOCIAL SCIENCE & MEDICINE, 2020, 246

[3]

[Anonymous], 2018, Framework for FDA's Real-World Evidence Program

[4]

[Anonymous], 2022, Impact of RWE on HTA Decision-Making

[5] Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward [J].

Baltussen, Rob ;

Marsh, Kevin ;

Thokala, Praveen ;

Diaby, Vakaramoko ;

Castro, Hector ;

Cleemput, Irina ;

Garau, Martina ;

Iskrov, Georgi ;

Olyaeemanesh, Alireza ;

Mirelman, Andrew ;

Mobinizadeh, Mohammedreza ;

Morton, Alec ;

Tringali, Michele ;

van Til, Janine ;

Valentim, Joice ;

Wagner, Monika ;

Youngkong, Sitaporn ;

Zah, Vladimir ;

Toll, Agnes ;

Jansen, Maarten ;

Bijlmakers, Leon ;

Oortwijn, Wija ;

Broekhuizen, Henk .

VALUE IN HEALTH, 2019, 22 (11) :1283-1288

[6]

CADTH, 2023, GUIDANCE REPORTING R

[7] HTA and MCDA solely or combined? The case of priority-setting in Colombia [J].

Castro, Hector E. ;

Moreno-Mattar, Ornella ;

Rivillas, Juan C. .

COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16

[8] Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration [J].

Chan, Kelvin ;

Nam, Seungree ;

Evans, Bill ;

de Oliveira, Claire ;

Chambers, Alexandra ;

Gavura, Scott ;

Hoch, Jeffrey ;

Mercer, Rebecca E. ;

Dai, Wei Fang ;

Beca, Jaclyn ;

Tadrous, Mina ;

Isaranuwatchai, Wanrudee .

BMJ OPEN, 2020, 10 (01)

[9] A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) [J].

Cherny, N. I. ;

Sullivan, R. ;

Dafni, U. ;

Kerst, J. M. ;

Sobrero, A. ;

Zielinski, C. ;

de Vries, E. G. E. ;

Piccart, M. J. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1547-1573

[10]

CoLab, Canada's Leader in Post-Market Drug Evaluation CADTH

← 1 2 3 →